Motavizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target RSV glycoprotein F
Clinical data
Pregnancy cat.  ?
Legal status  ?
Routes i.v.
Pharmacokinetic data
Protein binding non
CAS number 677010-34-3 N
ATC code None
UNII 50Y163LK8Q YesY
KEGG D06621 YesY
Chemical data
Formula C6476H10014N1706O2008S48 
Mol. mass Approximately 148 kDa
 N(what is this?)  (verify)

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.[1]

In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV.[2]


External links